Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Passwort vergessen?

Bitte geben Sie Ihren Ihre E-Mail-Adresse ein. Anweisungen zum Zurücksetzen des Passworts werden Ihnen umgehend per E-Mail übermittelt.

Literatur:

Entwicklung der target-orientieren Krebstherapie

G. Gastl, Innsbruck (Seite 11)

 

  1. Amedos M et al. Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncoloyg community?. Cancer Treat Rev 40: 1192-98, 2014
  2. Dietel M et al. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 22: 417-30, 2015
  3. Esposito A et al. Monitoring tumour-derived cell-free DNA in patients with solid tumours: clinical perspectives and research opportunities. Cancer Treat Rev 40: 648-55, 2014
  4. Francis G et al. Circulating cell-free tumour DNA in the management of cancer. Int J Mol Sci 16: 14122-42, 2015
  5. Gelao L et al. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an “innocent bystander”. Toxins (Basel) 6: 914-33, 2014
  6. Geynisman DM et al. Adherence to targeted oral anticancer medications. Discov Med 15: 231-41, 2013
  7. Grazia G et al. Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol 45: 929-949, 2014
  8. Jönsson B. Technology assessment for new oncology drugs. Clin Cancer Res 19: 6-11, 2013
  9. Kornek G et al. Targeted therapies in solid tumours: pinpointing the tomour’s Achilles heel. Curr Pharm Des 15: 207-42, 2009
  10. Lucchini E et al. Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opin Drug Saf 13: 535-49, 2014
  11. Ludwig WD. Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology. Z Evid Fortbild Qual Gesundhwes 106: 11-22, 2012
  12. Ribas A et al. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol 25: 291-96, 2013
  13. Rosland GV et al. Novel points of attack for targeted cancer therapy. Basi & Clin Pharm Tox 116: 9-18, 2015 
  14. Siravegna G et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21: 795-801, 2015 
  15. Smieliauskas F et al. Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. Pharmacoeconomics 32: 651-80, 2014
  16. Thompson JM et al. Approaches to identifying synthetic lethal interactions in cancer. Yale J Biol Med 88: 145-55, 2015
  17. Vera-Badillo FE et al. Benefit and harms of new anti-cancer drugs. Curr Oncol Rep 15: 270-75, 2013
  18. Wood KC. Mapping the pathways of resistance to targeted therapies. Cancer Res 21: 1-5, 2015

Target-orientierte Therapie von Tumoren der Lunge

F. Griesinger, Oldenburg (S. 18)

  1. (Fabrice Barlesi, Helene Blons, Michele Beau-Faller, Isabelle Rouquette, L'houcine Ouafik, Jean Mosser, Jean-Philippe Merlio, Pierre Paul Bringuier, Philippe Jonveaux, Cedric Le Marechal, Marc G. Denis, Frederique Madeleine Penault-Llorca, Didier Debieuvre, Jean-Charles Soria, Jacques Cadranel, Julien Mazieres, Pascale Missy, Franck Morin, Frederique Nowak, Gerard Zalcman. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 31, 2013 (suppl; abstr 8000)
  2. Schuette et al. Cancer Epidemiology and Prevention Cancer Epidemiol Biomarkers Prev; 24(8) August 2015; 1254-1261), 
  3. (Halbfass V, Prenzel R, Scriba D et al. Incidence of EGFR , KRAS, BAF, ALK and p53 alterations in a cohort of 159 consecutively tested patients from 1 DKG cervified lung cancer center and correlation with clinical characteristics. Onkologie 2013: 36;251)
  4. Sebastian et al. Dtsch Med Wochenschr 02014;1390: 2096–2100). 
  5. Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O’Byrne, Vera Hirsh, Tony Mok,Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer, Wu-Chou Su, Jaafar Bennouna,Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin SchulerPhase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.: J Clin Oncol 31:3327-3334
  6. Yi-Long Wu, Caicun Zhou, Cheng-Ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong-Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut L Geater. Afatinib versus cisplatin plus gemcitabine for fi rst-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213–22.
  7. 7 Lee CK et al. J Clin Oncol 2015;33(suppl; abstr 8072). LIT).
  8. James C-H Yang*, Lecia V Sequist*, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Shu Kam Mok, Martin Schuler, Nobuyuki Yamamoto,Chong-Jen Yu, Sai-Hong I Ou, Caicun Zhou, Daniel Massey, Victoria Zazulina, Yi-Long Wu. (Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 Lancet Oncol 2015; 16: 830–38)
  9. Oxnard GR, et al.: Clin Cancer Res 2011; 17: 5530-5537
  10. Yu H A, et al.: Clin Cancer Res 2013; 19: 2240-2247
  11. Jänne P et al. NEJM 2015
  12. Sequist et al. NEJM 2015
  13. Park et al. PSCO 8084, 2015
  14. Mok et al. IMPRESS Studie ESMO 2015
  15. Alice T. Shaw,Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse,Benjamin J. Solomon, Fiona Blackhall, Yi-Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro-Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne. Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. N Engl J Med 2013. DOI: 10.1056/NEJMoa1214886
  16. Benjamin J. Solomon, Tony Mok,Dong?Wan Kim, Yi?Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer,  Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. N Engl J Med 2014;371:2167-77. DOI: 10.1056/NEJMoa1408440
  17. S.-H. I. Ou, P. A. Jänne, C. H. Bartlett, Y. Tang, D.-W. Kim, G. A. Otterson, L. Crinò, P. Selaru, D. P. Cohen, J. W. Clark, G. J. Riely Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 25: 415-422; 2014 
  18. Alice T. Shaw,Dong-Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas,  Gregory J. Riely, Benjamin J. Solomon, Juergen Wolf, Michael Thomas, Martin Schuler, Geoffrey Liu, Armando Santoro, Yvonne Y. Lau, Meredith Goldwasser, Anthony L. Boral, Jeffrey A. Engelman. Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer. N Engl J Med 2014;370:1189-97. DOI: 10.1056/NEJMoa1311107 
  19. Justin F.Gainor, Daniel S.W.Tan,Tomasso De Pas, Benjamin J. Solomon, AziahAhmad, Chiara Lazzari,  Filippo de Marinis, Gianluca Spitaleri, Katherine Schultz, Luc Friboulet, Beow Y.Yeap, Jeffrey A. Engelman, Alice T. Shaw.Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res.2015 doi: 10.1158/1078-0432.CCR-14-3009
  20. Mok et al. PASCO 2015 #8059, 
  21. Felip et al. PASCO 2015 #8060
  22. Alice T. Shaw, Sai-Hong I. Ou, Yung-Jue Bang, D. Ross Camidge,Benjamin J. Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella-Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long Phi Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, Lesley M. Tye, James G. Christensen, Keith D. Wilner,  Jeffrey W. Clark, A. John IafrateCrizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer NEJM 2014; 371: 1963-1971
  23. Planchard D et al., PASCO 2015 Abstract #8006.
  24. Drilon A et al., PASCO 2015 Abstract #8007

Target-orientierte Therapie in der Uro-Onkologie

T. Otto, Neuss (S. 24)

Harnblasenkarzinom

 

  1. Lerner, SP Molecular Analysis for Therapy Choice, J.Urol 193: 8-9, 2015.
  2. Powles T et al. A phase II/III trial, double blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER ½ positive metastatic bladder cancer patients. J Clin Oncol 33: 4505, 2015.
  3. Seront E et al. Phase II study of dual phosphoinositol 3 kinase and mTOR inhibitor BEZ 235 in patients with locally advanced or metastatic TCC. J Clin Oncol 33: e15535, 2015.
  4. Bellmunt J et al. First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The international Borealis-1 trial. J Clin Oncol 33: 4503, 2015.
  5. Plimack ER Pembrolizumab for advanced urothelial cancer. J Clin Oncol 33: 4502, 2015.
  6. Lee JL PECULIAR study: Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer. J Clin Oncol (suppl.), 2014.
  7. Necchi A Phase II study of neoadjuvant sorafenib plus cisplatin and gemcitabine for patients with muscle invasive TCC of the bladder: Results at the end of first stage. J Clin Oncol (suppl.), 2014.
  8. Apolo AB A phase II study of cabozantinib in patients with relapsed or refractory metastatic urothelial carcinoma. J Clin Oncol (suppl.), 2014.
  9. Srinivas S et al. Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer. ASCO GU 294, 2015.
  10. Geldart TR SUCCINCT: A phase II single arm trial evaluating cisplatin and gemcitabine chemotherapy in combination with sunitinib as first line treatment of patients with advanced TCC. J Clin Oncol (suppl.), 2014.
  11. Houede et al. Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. ASCO GU 304, 2015
  12. Petrylak DP et al. Interim results of a randomized phase 2 study in second line advanced or metastatic urothelial carcinoma. ASCO GU: 295, 2015.
  13. Bajorin DF NeuACT, a phase II randomized open label trial of DN24-02: Updated analysis of HER2 expression,immune response,product parameters,and safety in patients with surgically resected HER21 urothelial cancer. J Clin Oncol (suppl.), 2014.

Nierenzellkarzinom

  1. Escudier B PFS as a surrogate endpoint of overall survival in patients with mRCC. Cancer 120:52-60,2014.
  2. Albiges L The impact of body mass index on treatment outcome of targeted therapy in mRCC. J Clin Oncol suppl 4576,2014.
  3. Clark J et al. Impact of targeted therapy on survival of mRCC patients treated with HD-IL-2. J Clin Oncol 33: e15609, 2015.
  4. Stenehjem DD et al. Extension of overall survival beyond objective response in patients with mRCC treated with high dose IL-2. J Clin Oncol 33: 4508, 2015.
  5. Alvarez AL A phase II study of pazopanib in patients with localized RCC to enable partial nephrectomy. J Clin Oncol suppl 4522,2014.
  6. Karam JA Phase II trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear renal cell carcinoma. J Clin Oncol (suppl.), 2014.
  7. Haas NB et al. Initial results from ASSURE. ASCO GU: 403, 2015.
  8. Motzer RJ Overall survival in renal cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370(18) 1769-1770,2014.
  9. Lee JL et al. Randomized phase II trial of sunitinib four week on and two week off versus two week on and one wek off in mRCC, ASCO GU: 427, 2015.
  10. Tomita Y Sunitiniv versus sorafenib in first line therapy for patients with mRCC with favourable or intermediate MSKCC risk factors. J Clin Oncol (suppl.), 2014.
  11. Escudier BJ Genotype correlations with blood pressure and efficacy outcomes from the randomized phase III AXIS trial of second line axitinib versus sorafenib in mRCC. J Clin Oncol suppl 4528,2014. 
  12. Tannir NM Everolimus versus sunitinib prospective evaluation in metastatic non clear cell carcinoma. J Clin Oncol suppl 4505,2014.
  13. Armstrong AJ et al. Final clinical results of a randomized phase II international trial of everolimus vs sunitinib in patientes with metastatic non clear cell RCC. J Clin Oncol 33: 4507, 2015.
  14. Escudier BJ et al. Efficacy of everolimus in poor risk patients. ASCO GU: 488, 2015.
  15. Bellmunt J et al. Metronomic therapy-new option for advanced kidney cancer. Lancet Oncology, in press.
  16. Motzer RJ et al. RECORD 4. J Clin Oncol 33: 4518, 2015
  17. Hutson TE Randomized phase III trial of temsirolimus versus sorafenib as second line therapy after sunitinib in patients with mRCC. JclinOncol 32:760-767,2014.
  18. Goebell PJ Subgroup analysis of a randomized sequential open-lable study (SWITCH) to evaluate efficacy and safety of sorafenib/sunitinib versus sunitinib/sorafenib in the treatment of mRCC. J Clin Oncol suppl 4567,2014.
  19. Michel MS SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib/sunitinib versus Sunitinib/Sorafenib in the treatment of mRCC. J Clin Oncol (suppl.), 2014.
  20. Escudier B Randomized controlled double blind cross over trial assessing treatment preference for pazopanib versus sunitinib in patients with mRCC:PISCES study. JclinOncol DOI:10.1200/JCO.2013.50.8267,2014.
  21. Davis ID EVERSUN:A phase II trial of everolimus alternating with sunitinib as first line therapy for advanced RCC. J Clin Oncol (suppl.), 2014.
  22. Knox JJ et al. Final overall analysis for the RECORD 3 study. J Clin Oncol 33: 4554, 2015.
  23. Bergmann L treatment algorithm for mRCC-recommendations based on evidence and clinical practice. Oncol Res Treat 37:136-141,2014.
  24. Plimack ER et al. Updated survival results from a randomized dose ranging phase II study of nivolumab in mRCC. J Clin Oncol 33: 4553, 2015.
  25. Henner M et al. DART Study. ASCO GU: 407, 2015.
  26. Motzer RJ et al. Randomized phase II 3 arm trial of lenvatinib, everolimus and lenvatinib+everolimus in patients with mRCC. J Clin Oncol 33: 4506, 2015.
  27. Hutson TE et al. Tivozanib vs Sorafenib targeted therapy for advanced RCC. J Clin Oncol 33: 4557, 2015.
  28. Figlin RA ADAPT: an ongoing international phase III randomized trial of autologous dendriticcell immunotherapy plus standard treatment in advanced RCC. J Clin Oncol (suppl.), 2014.
  29. Powles T A randomized phase II study of GDC-0980 versus everolimus in mRCC patients after targeted therapy. J Clin Oncol suppl 4525,2014.
  30. Powles T et al. A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractorx mRCC. ASCO GU: 409, 2015
  31. Choueiri TK et al. Cabozantinib versus Everolimus in advanced RCC. NEJM DOI:10.1056/NEJMoa1510016
  32. Motzer RJ et al. Nivolumab versus Everolimus in advanced RCC. NEJM DOI:10.1056/NEJMoa1510665

Therapie von Metastasen in der Wirbelsäule

M. Kröber, Hamburg (S. 33)

 

  1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7–33.
  2. Delank, Karl-Stefan; Wendtner, Clemens; Eich, Hans Theodor; Eysel, Peer. Behandlung von Wirbelsäulenmetastasen. The Treatment of Spinal Metastases, Dtsch Arztebl Int 2011; 108(5): 71-80.
  3. Patchell RA, Tibbs PA, Regine WF et al.: Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005 Aug 20–26; 366(9486): 643–8.
  4. Ghogawala Z, Mansfield FL, Borges LF: Spinal radiation before surgical decompression adversely affects outcomes of surgery for symptomatic metastatic spinal cord compression. Spine 2001; 26(7): 818–24
  5. Finn MA, Vrionis FD, Schmidt MH. Spinal radiosurgery for metastatic disease of the spine. Cancer Control. 2007 Oct;14(4):405-11. 
  6. Dupuy et al. Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial. Cancer 2010
  7. Koswig S, Budach V: Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther Onkol 1999; 175: 500–8.
  8. Ryu S, Fang Yin F, Rock J, et al.: Image-guided and intensity-modulated radiosurgery for patients with spinal metastasis. Cancer 2003; 97: 2013–8. 

Hodgkin-Lymphom: Belastungen minimieren und Möglichkeiten optimal korrigieren

F. Klein, München (S. 38)

 

  1. Radford J et al. N Engl J Med 2015; 372: 1598-607
  2. Raemaekers JMM et al. J Clin Oncol 2014; 32: 1188-1194
  3. Johnson PWM et al. 13-ICML, Lugano, Juni 2015
  4. Behringer K et al. Lancet 2015; 385: 1418-27
  5. Moskowitz CH et al. Lancet. 2015;385(9980):1853-62
  6. Ansell SM et al. N Engl J Med. 2015 Jan 22;372(4):311-9
  7. Moskowitz CH et al. Blood 2014; 124(21): 290